Leukemia

Latest News

August 18th 2023

Cross Q&A: Real-World Use of Low-Dose Dasatinib in CML

By Larry Anderson, MD, PhD, Adeel Khan, MD, MPH, MS, Prashant Kapoor, MD

Following a review of data with low-dose dasatinib in chronic myeloid leukemia, key opinion leaders from the Mayo Clinic and UT Southwestern consider its role in real-world practice.

Latest Videos

Chronic-Phase CML: The OPTIC Study

Team Introductions: CML Experts From UT Southwestern vs. Mayo Clinic

Mikkael A. Sekeres, MD, discusses how data from the phase 3 QuANTUM-First trial may advance the treatment field for patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.

Quizartinib May be Effective in an Older Population with FLT3-ITD+ AML

Relapsed/Refractory CLL: Overview of the Treatment Landscape

$Gregory W. Roloff, MD, indicates that brexucabtagene autoleucel did not yield significant positive findings in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who were MRD positive.$

Positive Brexu-Cel Findings Raise Questions of Treatment Sequencing in B-ALL

2-Minute Drill: Closing Thoughts on the 2023 ASCO Annual Meeting

2-Minute Drill: Shameless Plus From the 2023 ASCO Annual Meeting

2-Minute Drill: Biggest Winner From the 2023 ASCO Annual Meeting

2-Minute Drill: Trials Needing Follow-Up From the 2023 ASCO Annual Meeting

2-Minute Drill: FDA Action-Worthy Trials From the 2023 ASCO Annual Meeting

CME Content

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Iowa Oncology Society

Marla D. Lipsyc-Sharf, MD; Sheila Donnelly, MD

Video

Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities

Christine M. Lovly, MD, PhD, FASCO; Xiuning Le, MD, PhD; Hossein Borghaei, DO, MS; Lyudmila Bazhenova, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Texas Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Parth Khade, MD

Video

22nd Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

Omid Hamid, MD; Sapna Patel, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | North Carolina Oncology Association

Marla D. Lipsyc-Sharf, MD; Yan Ji, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Kimberly Ku, MD

Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Ghassan Abou-Alfa, MD, MBA

Multimedia

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Video

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Shubham Pant, MD, MBBS

Video

Proactive Adverse Event Management for HER2+ BTC Treatments

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCO

Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Yana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR

Video

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCR

Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Video

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

John H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MD

Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Eileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPH

Video

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Video

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

Multimedia

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Multimedia

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Audio

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Video

Cross-Disease Integration of Immunotherapy Innovations

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Video

Optimizing Treatment for Biliary Tract Cancers

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Multimedia

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Video

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

(CME Track) Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck - Post-CRT Decisions in the Locally Advanced Setting

Quynh-Thu Le, MD, FACR, FASTRO; Vlad C. Sandulache, MD, PhD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Rocky Mountain Oncology Society

Seth A. Wander, MD, PhD; Kara M. Schenk, MD

Virtual Event

Oncology Town Hall - Translating the Latest Updates Into the Care of Patients With AML in Community Practices

April 9, 2026

In-Person + Virtual Event

11th Annual School of Gastrointestinal Oncology® (SOGO®)

April 11, 2026

In-Person + Virtual Event

Tumor Board: Clinical Integration of Molecular Profiling in Glioma - Transforming the Use of Targeted Therapy

April 20, 2026

Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

Video

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MS

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Video

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Multimedia

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Multimedia

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Multimedia

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Video

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Audio

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Multimedia

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Audio

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Video

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

More News

Indirect Comparison of Acalabrutinib Versus Zanubrutinib in RR CLL: Safety Analysis

ByAlan P. Skarbnik, MD, Novant Health Cancer Institute,Ryan W. Jacobs, MD, Atrium Health Levine Cancer Institute

August 10th 2023

Key safety data from the indirect comparison study of acalabrutinib versus zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Combined with chemotherapy, blinatumomab appears tolerable and beneficial in a subgroup of pediatric patients with B-cell acute lymphoblastic leukemia in first relapse but does not yield better survival outcomes in the overall population.

Blinatumomab Improves OS/DFS in Low-Risk, Relapsed ALL Subgroup

ByNicholas Wrigley

August 6th 2023

Combined with chemotherapy, blinatumomab appears tolerable and beneficial in a subgroup of pediatric patients with B-cell acute lymphoblastic leukemia in first relapse but does not yield better survival outcomes in the overall population.

Olverembatinib Study in Patients With Heavily Pretreated Chronic Myeloid Leukemia

ByLarry Anderson, MD, PhD,Adeel Khan, MD, MPH, MS,Prashant Kapoor, MD,Wilson Gonsalves, MD,Abhishek Mangaonkar, MBBS,Kebede Begna, MD

August 4th 2023

A comprehensive review of chronic myeloid leukemia olverembatinib data led by expert Kebede Begna, MD, from the Mayo Clinic team.

Cross Q&A: Arterial Occlusive Events With Ponatinib in the PACE Trial

ByLarry Anderson, MD, PhD,Adeel Khan, MD, MPH, MS,Prashant Kapoor, MD,Wilson Gonsalves, MD,Abhishek Mangaonkar, MBBS,Kebede Begna, MD

August 4th 2023

Following a review of the retrospective analysis of PACE, experts reflect on its importance in understanding the risk of arterial occlusive events with ponatinib.

Indirect Comparison of Acalabrutinib Versus Zanubrutinib in RR CLL: Efficacy Analysis

ByAlan P. Skarbnik, MD, Novant Health Cancer Institute,Ryan W. Jacobs, MD, Atrium Health Levine Cancer Institute

August 3rd 2023

Alan Skarbnik, MD, and Ryan Jacobs, MD, review efficacy data from the indirect comparison study of acalabrutinib versus zanubrutinib in relapsed/refractory chronic lymphocytic leukemia.

Clinical Trials With BTK Inhibitors in Relapsed/Refractory CLL

ByAlan P. Skarbnik, MD, Novant Health Cancer Institute,Ryan W. Jacobs, MD, Atrium Health Levine Cancer Institute

August 3rd 2023

Focused discussion on key clinical trial data behind currently available BTK inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia.

The potential reduction in relapse in patients with unresectable chronic lymphocytic leukemia appears to happen regardless of minimal residual disease status 3 months post-treatment and immunoglobulin heavy-chain variable region mutational status.

Ibrutinib/Venetoclax Appears to Reduce Clinical/Molecular Relapse in CLL

ByNicholas Wrigley

July 29th 2023

The potential reduction in relapse in patients with unresectable chronic lymphocytic leukemia appears to happen regardless of minimal residual disease status 3 months post-treatment and immunoglobulin heavy-chain variable region mutational status.

Chronic Myeloid Leukemia: Retrospective Analysis of the PACE Study

ByLarry Anderson, MD, PhD,Adeel Khan, MD, MPH, MS,Prashant Kapoor, MD,Wilson Gonsalves, MD,Abhishek Mangaonkar, MBBS,Kebede Begna, MD

July 28th 2023

A focused discussion led by expert Abhishek Mangaonkar, MBBS, on a retrospective analysis elucidating arterial occlusive events within the PACE study.

Cross Q&A: Ponatinib Dosing in Relapsed/Refractory Chronic-Phase CML

ByLarry Anderson, MD, PhD,Adeel Khan, MD, MPH, MS,Prashant Kapoor, MD,Wilson Gonsalves, MD,Abhishek Mangaonkar, MBBS,Kebede Begna, MD

July 28th 2023

Expert perspectives from the Mayo Clinic and UT Southwestern teams on applications of the OPTIC study and optimal ponatinib dosing in chronic myeloid leukemia.

JZP458 is part of a multi-agent chemotherapy regimen for lymphoblastic lymphoma and acute lymphoblastic leukemia, and can be used for adult and pediatric patients.

CHMP Expresses Positive Opinion on JZP458 in Leukemia and Lymphoma Subtypes

ByNicholas Wrigley

July 25th 2023

JZP458 is part of a multi-agent chemotherapy regimen for lymphoblastic lymphoma and acute lymphoblastic leukemia, and can be used for adult and pediatric patients.

Data from a phase 1b dose escalation and expansion study highlight an encouraging duration of remission using APVO436 plus venetoclax and azacitidine in patients with acute myeloid leukemia.

APVO436 Combo Yields Favorable Responses in Acute Myeloid Leukemia

ByNicholas Wrigley

July 21st 2023

Data from a phase 1b dose escalation and expansion study highlight an encouraging duration of remission using APVO436 plus venetoclax and azacitidine in patients with acute myeloid leukemia.

Data from the phase 3 QuANTUM-First trial support the FDA’s approval of quizartinib for managing FLT3-ITD–positive acute myeloid leukemia.

FDA Approves Quizartinib for Newly Diagnosed FLT3-ITD+ AML

ByRuss Conroy

July 20th 2023

Data from the phase 3 QuANTUM-First trial support the FDA’s approval of quizartinib for managing FLT3-ITD–positive acute myeloid leukemia.

Findings from a phase 2 study may inform the design of future trials assessing fecal microbiota transplants in patients with acute myeloid leukemia.

Fecal Microbiota Transplant Yields no Effect on Infection Incidence in AML

ByNicholas Wrigley

July 19th 2023

Findings from a phase 2 study may inform the design of future trials assessing fecal microbiota transplants in patients with acute myeloid leukemia.

$Factors including measurable residual disease and CAR T-cell expansion appear to predict duration of response following JCAR014 in those with relapsed or refractory chronic lymphocytic leukemia in a phase 1/2 trial.$

CD19 CAR T Cell Therapy Yield High MRD-Negativity in R/R CLL

ByRuss Conroy

July 13th 2023

Factors including measurable residual disease and CAR T-cell expansion appear to predict duration of response following JCAR014 in those with relapsed or refractory chronic lymphocytic leukemia in a phase 1/2 trial.

The agent will be evaluated in a phase 1 study for patients with several myeloid malignancies, in which investigators will identify a recommended phase 2 dose.

Novel MDM2 Degrader KT-253 Receives FDA Orphan Drug Designation In AML

ByNicholas Wrigley

June 30th 2023

The agent will be evaluated in a phase 1 study for patients with several myeloid malignancies, in which investigators will identify a recommended phase 2 dose.

High Concordance Seen Between MRD Measurement by MFC and FGT in Infants with KMT2A-r ALL

ByAmerican Society for Transplantation and Cellular Therapy

June 23rd 2023

Pediatric patients with acute lymphoblastic leukemia and have KMT2A rearrangements were evaluated in a recent study published in the British Journal of Haematology.

NGS-MRD Panel Is “Highly Sensitive, Accurate” in AML

ByAmerican Society for Transplantation and Cellular Therapy

June 23rd 2023

A study regarding next-generation sequencing evaluated minimal residual disease in patients with acute myeloid leukemia.

The combination of venetoclax and ibrutinib may yield a long-lasting treatment-free remission among patients with high-risk chronic lymphocytic leukemia.

Venetoclax Combo May Help Achieve MRD Negativity in High-Risk CLL

ByNicholas Wrigley

June 22nd 2023

The combination of venetoclax and ibrutinib may yield long-lasting treatment-free remission among patients with high-risk chronic lymphocytic leukemia.

Blinatumomab has been granted full approval by the FDA for patients with B-cell acute lymphoblastic leukemia of minimal residual disease of 0.01% or more.

FDA Gives Full Approval to Blinatumomab in MRD-Positive B-Cell ALL

ByAriana Pelosci

June 21st 2023

Blinatumomab has been granted full approval by the FDA for patients with B-cell acute lymphoblastic leukemia and minimal residual disease of 0.01% or more.

$Investigators pause their evaluation of SC-DARIC33 in pediatric relapsed/refractory acute myeloid leukemia following a grade 5 serious adverse effect in the phase 1 PLAT-08 trial.$

Phase 1 Trial of SC-DARIC33 in Pediatric R/R Acute Myeloid Leukemia Pauses

ByRuss Conroy

June 14th 2023

Investigators pause their evaluation of SC-DARIC33 in pediatric relapsed/refractory acute myeloid leukemia following a grade 5 serious adverse effect in the phase 1 PLAT-08 trial.

2-Minute Drill: Most Practice-Changing Trial From the 2023 ASCO Annual Meeting

ByKristie L. Kahl

June 13th 2023

Thought leaders from various institutions offered their take on the most practice-changing trial that came out of the 2023 ASCO Annual Meeting.

2-Minute Drill: The Biggest Surprise From the 2023 ASCO Annual Meeting

ByKristie L. Kahl

June 12th 2023

Thought leaders from various institutions offered their take on the biggest surprise that came out of the 2023 ASCO Annual Meeting.

Investigators identify only 1 death related to treatment with acalabrutinib among older, frail patients with chronic lymphocytic leukemia in the phase 2 CLL-FRAIL trial.

Acalabrutinib Yields No Unexpected Safety Signals in Older CLL Population

ByBrielle Benyon

June 9th 2023

Investigators identify only 1 death related to treatment with acalabrutinib among older, frail patients with chronic lymphocytic leukemia in the phase 2 CLL-FRAIL trial.

Adding blinatumomab to Interfant-06 chemotherapy appears to be feasible and safe in the treatment infants with acute lymphoblastic leukemia in a phase 2 trial.

Blinatumomab/Chemo Shows High-Level Efficacy in Infant Leukemia Subtype

ByRuss Conroy

June 9th 2023

Adding blinatumomab to Interfant-06 chemotherapy appears to be feasible and safe in the treatment infants with acute lymphoblastic leukemia in a phase 2 trial.

$Zanubrutinib and acalabrutinib produce similar safety profiles in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia in the phase 3 ASCEND and APLINE trials.$

Acalabrutinib Yields Similar Survival as Zanubrutinib in R/R CLL

ByRyan Scott,Caroline Seymour

June 8th 2023

Zanubrutinib and acalabrutinib produce similar safety profiles in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia in the phase 3 ASCEND and APLINE trials.